Revenue in the medical technology market worldwide 2016-2030, by segment

Revenue in the medical technology market worldwide from 2016 to 2030, by segment

Revenue in the medical technology market worldwide is projected to reach about 666 billion dollars in 2026, of which medical devices account for about 572 billion and in vitro diagnostics for about 94 billion. The market has grown from about 430 billion dollars in 2016. Few industry series are as steady as the revenue of the medical technology market, a market whose demand is driven less by fashion or the business cycle than by the simple arithmetic of ageing populations and rising chronic disease. On the 2026 figures, medical devices at about 572 billion dollars make up roughly 86 percent of the market and in vitro diagnostics at about 94 billion the remaining 14 percent, together giving a total of about 666 billion. What makes the series worth studying closely is not any single year but the shape of the whole, a market that has more than half again in size over fifteen years without a single dramatic year, the very opposite of the technology markets it is often compared with.

The market is forecast to reach about 826 billion dollars by 2030, growing at about 5.5 percent a year. The figures sit within our medical technology industry and medtech industry data coverage.

From 430 to 826 billion: medical technology revenue grew from about 430 billion dollars in 2016 to a projected 666 billion in 2026 and a forecast 826 billion by 2030.

Medical devices are the larger and faster-growing of the two segments, expanding at about 5.8 percent a year against about 3.8 percent for diagnostics, themes our medtech market and global pharmaceutical industry coverage explores.

A note on the data. The figures show revenue in the medical technology market worldwide from 2016 to 2030, by segment, in billion dollars, from Statista Market Insights. The market splits into medical devices and in vitro diagnostics, and years from 2026 are forecasts. Because the figures are modeled estimates at manufacturer price level and different research firms define the boundaries of the industry differently, market size estimates vary widely between sources, from roughly 570 billion dollars to over 700 billion. The market covers devices and products used for prevention, diagnosis and treatment of disease, and after pharmaceuticals it is the most important category of medical products, with revenue allocated to the country where the money is spent.

Medical Technology Revenue by Segment

The table shows revenue in the medical technology market worldwide by year and segment. It shows medical devices growing from about 368 billion dollars in 2016 to a forecast 717 billion by 2030, while in vitro diagnostics grows from about 62 billion to about 109 billion. Reading down the table shows an industry that has added roughly 236 billion dollars of annual revenue in a decade, with medical devices supplying about 204 billion of that and diagnostics about 32 billion. Because the figures use current exchange rates and modeled estimates, the totals are best read as a consistent series showing the shape and pace of growth rather than as precise absolute values for any single year. The single most revealing comparison in the table is between 2022 and 2024, where diagnostics fell while devices rose sharply, the clearest possible illustration of how differently the two halves of the market behave.

What Are the Segments of the Market?

The medical technology market splits into two segments. Medical devices, worth about 572 billion dollars in 2026, cover the instruments and machines used to prevent, diagnose and treat disease. In vitro diagnostics, worth about 94 billion, cover tests performed outside the body. The division of medical technology into devices and diagnostics is the most important split in the industry, because the two halves behave very differently, with devices tied to procedures and implants and diagnostics tied to testing volumes. Medical devices about 572 billion dollars and in vitro diagnostics about 94 billion together make up the 666 billion dollar medical technology market of 2026, a ratio of roughly six to one in favour of devices. The choice to split medical technology into devices and diagnostics is not arbitrary, since the two halves sell to different budgets, move with different drivers and are dominated by different companies, and treating them as one market obscures more than it reveals.

The gap between the two segments is wide and widening, as devices grow faster than diagnostics, a divergence our biggest companies by market value coverage frames through the companies that dominate each.

Devices dominate: medical devices make up about 86 percent of the medical technology market in 2026, worth about 572 billion dollars, against 14 percent for diagnostics.

Medical devices make up about 86 percent of the medical technology market in 2026 and in vitro diagnostics about 14 percent, a split that has shifted only slightly over the past decade despite the pandemic surge in testing. The stability of the split between devices and diagnostics, at roughly 86 to 14, is striking given the upheaval of the pandemic years, and shows how quickly the market reverted to its long-term structure once testing volumes normalised. The 86 to 14 split has proved one of the more durable structural facts about medical technology, surviving a pandemic that briefly seemed likely to rewrite it entirely.

How Fast Has the Market Grown?

The medical technology market has grown every year of the past decade apart from a pandemic slowdown. Revenue rose from about 430 billion dollars in 2016 to about 666 billion in 2026, an increase of roughly 55 percent, or about 4.5 percent a year on average. The growth of the medical technology market over the past decade has been remarkably consistent, with the pandemic providing the only real interruption, and even that proved temporary rather than structural. Revenue rose from about 430 billion dollars in 2016 to about 508 billion in 2020, about 612 billion in 2024 and about 666 billion in 2026, a compound annual growth rate of roughly 4.5 percent over the decade. The consistency of growth in medical technology is its most commercially valuable feature, because it allows manufacturers to plan capacity, investors to model cash flows and health systems to budget with a confidence that few other industries permit.

The steady growth reflects ageing populations, rising chronic disease and the spread of advanced devices into new markets, drivers our US population coverage frames.

Steady compounding: the market has grown every year of the decade apart from the pandemic slowdown of 2020, at an average of about 4.5 percent a year.

Growth was slowest in 2020, when elective procedures were postponed and device sales fell, and fastest in 2021 and 2022, as postponed operations were caught up and diagnostic testing surged. The pandemic years distorted both halves of the market in opposite directions, suppressing device sales as operations were postponed while sending diagnostics revenue sharply higher, and the two effects largely cancelled out at the market level. Looking across the whole series, the market has proved remarkably resilient, absorbing a global pandemic with barely a pause in its long climb and returning quickly to its underlying trend. The recovery from 2020 was rapid and complete, and by 2022 the market had returned to the level its pre-pandemic trend would have predicted, suggesting the disruption delayed demand rather than destroying it.

The Medical Devices Segment

Medical devices revenue is projected to reach about 572 billion dollars in 2026 and about 717 billion by 2030, growing at about 5.8 percent a year. The segment has grown from about 368 billion dollars in 2016, adding more than 200 billion in a decade. Medical devices are the engine of the medical technology market, accounting for the great majority of both revenue and growth, and their steady expansion underpins the whole forecast for the industry. Medical devices revenue rose from about 368 billion dollars in 2016 to about 522 billion in 2024 and a projected 572 billion in 2026, and is forecast to reach about 717 billion by 2030. The device segment carries the whole market on its back, and any serious forecast of medical technology is in practice a forecast of what happens to implants, imaging systems and surgical equipment over the coming years.

The strength of the device segment reflects steady demand for implants, imaging systems and surgical equipment, along with the shift of procedures to outpatient settings, a shift our US GDP coverage frames through healthcare spending.

The engine of growth: medical devices revenue rose from about 368 billion dollars in 2016 to a projected 572 billion in 2026 and a forecast 717 billion by 2030.

Within devices, cardiology is the largest category at about 84 billion dollars in 2026, followed by diagnostic imaging and orthopedics, reflecting both the burden of heart disease and the high value of the implants used to treat it. The breadth of the device segment, spanning everything from disposable surgical instruments to imaging suites costing millions, is one reason its growth has been so steady, since no single product or patent can move the whole. Looking ahead, the device segment seems likely to keep its dominant share, with robotics, AI-enabled products and the shift of procedures to outpatient settings all supporting continued growth. The steady climb of devices through every kind of economic weather, from the financial crisis to the pandemic to the inflation of recent years, is the strongest evidence available for the defensive character of the industry.

The In Vitro Diagnostics Segment

In vitro diagnostics revenue is projected at about 94 billion dollars in 2026, rising to about 109 billion by 2030. The segment grew sharply during the pandemic, peaking above 90 billion in 2022, then dipped as testing volumes normalised. In vitro diagnostics is the smaller and more volatile half of the market, and its recent history is dominated by the extraordinary surge in testing during the pandemic and the equally sharp normalisation that followed. In vitro diagnostics revenue rose from about 62 billion dollars in 2016 to a pandemic peak of about 92 billion in 2022, dipped to about 90 billion in 2024, and is projected at about 94 billion in 2026 and 109 billion by 2030. The diagnostics series is the more interesting of the two to read, because it contains a natural experiment, showing what happens when an entire market is briefly given several years of demand at once and then has it taken away.

The pandemic distortion is the defining feature of the diagnostics series, with a surge in testing followed by a return to more normal volumes, a pattern our chemical industry coverage frames through the reagents behind the tests.

A pandemic spike: in vitro diagnostics revenue surged to about 92 billion dollars in 2022 as testing boomed, dipped as volumes normalised, and is forecast to reach 109 billion by 2030.

Growth in diagnostics has since resumed at a slower pace of about 3.8 percent a year, driven by molecular testing, point-of-care devices and the spread of routine screening into more countries. The normalisation of diagnostics after the pandemic left the segment roughly where its pre-pandemic trend would have put it, suggesting the surge pulled demand forward rather than permanently expanding the market.

Which Segment Grows Fastest?

The two segments grow at different speeds. Medical devices are forecast to grow at about 5.8 percent a year between 2026 and 2030, while in vitro diagnostics grows at about 3.8 percent, giving the market as a whole a rate of about 5.5 percent. The difference in growth rates between the two segments is small in any single year but compounds into a significant divergence over the forecast period, steadily shifting the balance of the industry toward devices. Medical devices are forecast to grow at about 5.8 percent a year from 2026 to 2030 against about 3.8 percent for in vitro diagnostics, giving the market as a whole about 5.5 percent. A two percentage point gap in growth rates sounds trivial, but compounded over a decade it reshapes an industry, and that is precisely what is happening between devices and diagnostics.

The faster growth of devices reflects both the larger base and the stronger demand for implants and imaging, a divergence our big tech revenue coverage sets against far faster technology markets.

Devices grow faster: medical devices are forecast to grow at about 5.8 percent a year to 2030 against about 3.8 percent for in vitro diagnostics.

At those rates, medical devices will add about 145 billion dollars of annual revenue between 2026 and 2030, while diagnostics adds about 15 billion, so devices account for more than 90 percent of the growth. The concentration of growth in devices means the forecast for the whole market is essentially a forecast for devices, with diagnostics contributing only a small fraction of the additional revenue expected by 2030. That devices supply more than nine tenths of the growth to 2030 is the single most important fact in the forecast, and it means the outlook for medical technology is essentially the outlook for surgery and implants.

The Outlook to 2030

The market is forecast to grow from about 666 billion dollars in 2026 to about 826 billion by 2030, an increase of about 160 billion. Medical devices contribute about 145 billion of that and in vitro diagnostics about 15 billion. The forecast to 2030 is unusually confident by the standards of technology markets, because the underlying demand drivers are demographic certainties rather than matters of consumer preference or technological gamble. The market grows from about 666 billion dollars in 2026 to about 826 billion by 2030, with devices rising from about 572 to about 717 billion and diagnostics from about 94 to about 109 billion. Forecasts of this market are more credible than most because the demand comes from demography, and the number of people who will be over seventy in 2030 is already known with considerable precision today.

The concentration of growth in devices will push their share of the market above 86 percent by 2030, a shift our global stock markets by country coverage frames through the listed companies behind them.

Devices supply 90%: of the roughly 160 billion dollars of growth expected between 2026 and 2030, medical devices contribute about 145 billion and diagnostics about 15 billion.

The forecast assumes no repeat of the pandemic testing surge, so diagnostics grows steadily from its normalised base rather than spiking, while devices continue their long, steady climb. The risk to the forecast lies mostly on the upside, since a faster than expected adoption of surgical robotics or AI-enabled devices could lift device growth above the assumed rate.

How the Segments Changed Since 2016

A few milestones map the trajectory. The market passed 500 billion dollars in 2019, reached about 666 billion in 2026, and is forecast to approach 750 billion by 2028 and 826 billion by 2030, on its way toward the one trillion mark in the following decade. Tracking the milestones of the medical technology market shows a series that compounds quietly rather than spiking, adding a few tens of billions of dollars most years without drama.

Each milestone reflects the steady compounding of a market with unusually predictable demand, a contrast our crypto market coverage draws against far more volatile technology markets.

Both nearly doubled: from 2016 to 2030 medical devices revenue roughly doubles from 368 to 717 billion dollars and diagnostics from 62 to 109 billion.

The pace of the climb has been remarkably even, with the market adding roughly 20 to 40 billion dollars of annual revenue most years, apart from the pandemic distortion of 2020 to 2022. The evenness of the climb is itself the most telling feature of the series, marking medical technology out from the technology markets it is often grouped with, where growth arrives in waves rather than in a steady line. The absence of drama in the series is what makes it useful, since a market that adds a predictable few tens of billions a year is one that can be planned around rather than merely hoped about.

Where Is the Revenue Earned?

The United States generates the most medical technology revenue of any country, about 245 billion dollars in 2026, more than a third of the world total. China, Germany and Japan follow, though each is far behind. Where medical technology revenue is earned reveals as much about healthcare systems as about the industry itself, since the countries that spend most per person on health are also where the newest devices reach patients first. The United States about 245 billion dollars in 2026 is followed at a distance by China on roughly 62 billion, Germany on about 41 billion and Japan on about 38 billion. The geographic concentration of medical technology revenue is one of the least discussed facts about the industry, and one of the most consequential for questions of access and equity in global health.

The American lead reflects high healthcare spending and the largest hospital market in the world, a pattern our Nasdaq stock market coverage frames through the listed medtech giants based there.

The US leads: the United States generates about 245 billion dollars of medical technology revenue in 2026, more than a third of the world total.

Outside the United States, the established centres are Western Europe and Japan, while China is the fastest-growing large market and is expected to account for a far larger share of revenue by the end of the decade. The concentration of revenue in a handful of wealthy countries is one of the enduring features of medical technology, and one reason access to the newest devices remains so uneven around the world.

The Biggest Device Categories

Within medical devices, cardiology is the largest category at about 84 billion dollars in 2026. Diagnostic imaging, orthopedics, ophthalmics and general surgery follow, together making up the bulk of the device market alongside a long tail of smaller categories. The device half of the market divides into categories that map onto medical specialties, so the size of each reflects both the burden of the underlying disease and the value of the technology used to treat it. Cardiology devices about 84 billion dollars in 2026 lead the device market, ahead of diagnostic imaging, orthopedics, ophthalmics and general surgery, which together account for most of the rest.

The dominance of cardiology reflects the global burden of heart disease and the high value of pacemakers, stents and heart valves, a market our AI market size coverage now touches as algorithms enter the reading of cardiac scans.

Cardiology leads: cardiology devices are the largest category within medical devices at about 84 billion dollars in 2026, ahead of diagnostic imaging and orthopedics.

Diagnostic imaging is the category being reshaped fastest, as artificial intelligence takes on more of the reading of scans, while orthopedics is being reshaped by robotic assistance in joint replacement. The pattern across device categories has held steady for years, with cardiology far ahead and imaging, orthopedics and ophthalmics clustered behind, though robotics and AI-enabled products grow far faster than any of them.

Medical Technology Revenue in Numbers

A few numbers capture the market. Revenue in the medical technology market worldwide is about 666 billion dollars in 2026, medical devices account for about 572 billion, in vitro diagnostics for about 94 billion, and the market is forecast to reach 826 billion by 2030. These figures together map a market of unusual predictability, large and steadily growing, dominated by medical devices and forecast to keep climbing at a mid single-digit rate through the end of the decade. Read as a whole, the series describes a market whose growth is slow by technology standards and fast by industrial ones, and whose reliability is precisely what makes it valuable.

The figures matter because medical technology revenue tracks both demographic change and technological progress, a link our artificial intelligence statistics and Apple employee data coverage touches through connected health devices.

Together these figures show a market that has grown steadily for a decade, is dominated by medical devices, and is forecast to keep growing at about 5.5 percent a year through the end of the decade. For now, revenue in the medical technology market stands as one of the steadiest series in global industry, a quiet but relentless climb underpinned by demographics rather than fashion.

Medical Technology Revenue: The Big Picture

Taken together, revenue in the medical technology market from 2016 to 2030 maps a market growing steadily from 430 billion dollars to a forecast 826 billion, a story our cloud market coverage sets against faster-growing technology sectors.

Whether growth accelerates will depend on how quickly artificial intelligence and robotics move from promise to routine practice, but for now the market climbs at a steady and highly predictable pace, alongside the hardware markets in our VR headset market overview.

Frequently Asked Questions: Medical Technology Revenue